Historical record - last NADAC effective date: 3/20/2024
Product Information
PREGABALIN 300 MG CAPSULE is a generic product labeled by Cipla USA Inc., priced at $0.0864 per EA under NDC 69097096205. Its NADAC has been published 241 times since Aug 21, 2019.
FDA first approved this application on Jul 19, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Cipla USA Inc.NDC
69097096205
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
3/20/2024
Active Ingredients
PREGABALINApproval Type
Generic (ANDA)
FDA Application
ANDA211384FDA Approved
7/19/2019
TE Code
AB
On Market Since
7/19/2019
Price Statistics
The NADAC for PREGABALIN 300 MG CAPSULE has been published 241 times since Aug 21, 2019, and over the history we have for it it has declined 63.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0864 per EA |
|---|---|
| All-time high | $0.2379 (Sep 11, 2019) |
| All-time low | $0.0864 (Mar 20, 2024) |
| Median price | $0.1241 |
| Average price | $0.1365 |
| Largest weekly change | -21.5% (Feb 23, 2022) |
| Weeks tracked | 241 |
| Tracking since | Aug 21, 2019 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
-10.3%
5Y
-33.6%
All
-63.7%
Last surveyed Mar 27, 2024 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 23% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cipla USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
PREGABALIN market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PREGABALIN 300 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for PREGABALIN 300 MG CAPSULE, manufactured by Cipla USA Inc., is $0.0864 per EA (NDC 69097096205), effective Mar 27, 2024.
How has the price of PREGABALIN 300 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for PREGABALIN 300 MG CAPSULE has declined 63.7%. It has been tracked across 241 weekly CMS publications since Aug 21, 2019.
What are the highest and lowest recorded NADAC prices for PREGABALIN 300 MG CAPSULE?
Since Aug 21, 2019, the NADAC for PREGABALIN 300 MG CAPSULE has ranged from a low of $0.0864 (Mar 20, 2024) to a high of $0.2379 (Sep 11, 2019), with a median of $0.1241 per EA.
Are there cheaper alternatives to PREGABALIN 300 MG CAPSULE?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, PREGABALIN 300 MG CAPSULE, is $0.0665 per EA — about 23% below PREGABALIN 300 MG CAPSULE.
Who manufactures PREGABALIN 300 MG CAPSULE?
PREGABALIN 300 MG CAPSULE (NDC 69097096205) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.